About us
Overview
Our team
Investors
Innovation
Overview
Pipeline
Technology
Clinical trials
Overview
Usher 1B
Stargardt
News
Careers
Contact
English
English
Italiano
Search
News
News
Filter by:
All categories
All categories
Press Release
Publication
All years
2024
2023
2022
2021
Archive
Reset
03.12.2024
Press Release
AAVantgarde announces oral presentation of LUCE-1 clinical study at FLORetina 2024
02.12.2024
Press Release
AAVantgarde Bio Announces FDA Orphan Drug Designation for AAVB-081
28.10.2024
Press Release
AAVantgarde Founder and CSO is elected as President of the European Society of Gene and Cell Therapy (ESGCT)
21.10.2024
Press Release
AAVantgarde appoints Ms. Lauren Kaskiel as Chief Business Officer
08.10.2024
Press Release
AAVantgarde announces 3 oral presentations at ESGCT 2024
16.09.2024
Press Release
AAVantgarde announces first patient dosed with AAVB-081 in FIH Phase 1/2 LUCE-1 study for retinitis pigmentosa related to USH1B
09.09.2024
Press Release
AAVantgarde appoints Dr. Jayashree Sahni as Chief Medical Officer
03.05.2024
Press Release
AAVantgarde presents the design of its innovative LUCE-1 trial for USH1B at the 9th Annual Retinal Cell and Gene Therapy Innovation Summit
24.04.2024
Press Release
AAVantgarde announces updated NHP data for its Stargardt program to be presented at ARVO 2024
23.04.2024
Press Release
AAVantgarde presents large animal models preclinical data at ASGCT 2024
31.01.2024
Press Release
AAVantgarde appoints Nina (Ekaterini) Kotsopoulou, Ph.D., as Chief Technical Officer
08.11.2023
Press Release
AAVantgarde Appoints Dr. Peter K. Kaiser to the Board of Directors
30.10.2023
Press Release
AAVantgarde Appoints Michael Heffernan as Chairman of its Board of Directors
12.09.2023
Press Release
AAVantgarde Appoints Dr. Doug Kerr to the Board of Directors
06.06.2023
Press Release
AAVantgarde Closes €61 Million Series A Financing to Advance Two Therapeutic Programs into the Clinic
Load more